Changes in liver and spleen stiffness after transarterial chemoembolization for hepatocellular carcinoma and role in predicting hepatic decompensation

doi:10.3748/wjg.122240

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 43

This Article

(3)

(2)

(0)

(2)

Peer-Review Report of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Nov 21, 2026; 32(43): 122240
Published online Nov 21, 2026. doi: 10.3748/wjg.122240

Table 1 Baseline characteristics of hepatocellular carcinoma patients undergoing transarterial chemoembolization, mean ± SD/n (%)

Characteristics	n = 102
Age (years)	63.8 ± 10.1
Males	86 (84.3)
Body mass index (kg/m²)	24.1 ± 4.2
Etiology
Hepatitis B virus infection	41 (40.2)
Hepatitis C virus infection	25 (24.5)
MASLD	9 (8.8)
Alcohol-related liver disease	17 (16.7)
BCLC stage
A	32 (31.4)
B	62 (60.7)
C	8 (7.8)
Previous treatment
No previous treatment	47 (46.1)
Locoregional treatment	50 (49.0)
Systemic therapy	1 (1.0)
Liver resection or lobectomy	4 (3.9)
Tumor characteristics
Tumor size (largest diameter)
< 5 cm in size	71 (69.6)
5-8 cm in size	16 (15.7)
> 8 cm in size	15 (14.7)
Unilobar	69 (67.6)
Bilobar	33 (32.4)
Single nodule	33 (32.4)
Multiple nodules	69 (67.6)
Non-selective beta-blocker use	25 (24.5)
Spleen diameter (cm)	10.9 ± 2.8
Platelet count (μL)	153922 ± 91509
Alpha-fetoprotein (IU/mL)	4046 ± 19144
Portal vein thrombosis	22 (21.6)
mALBI grade
Grade 1	39 (38.2)
Grade 2a	30 (29.4)
Grade 2b	26 (25.5)
Grade 3	7 (6.9)
MELD score	9.2 ± 3.0
Child-Pugh class
A	87 (85.3)
B	15 (14.7)

BCLC: Barcelona Clinic Liver Cancer; mALBI: Modified albumin-bilirubin; MASLD: Metabolic dysfunction-associated steatotic liver disease; MELD: Model for end-stage liver disease.

Full Size Table

Citation: Pattarawongpaiboon C, Thaimai P, Boonkaya S, Sriyudthsak K, Lertsanguansinchai S, Ananchuensook P, Sriphoosanaphan S, Pinjaroen N, Treeprasertsuk S, Komolmit P, Thanapirom K. Changes in liver and spleen stiffness after transarterial chemoembolization for hepatocellular carcinoma and role in predicting hepatic decompensation. World J Gastroenterol 2026; 32(43): 122240
URL: https://www.wjgnet.com/1007-9327/full/v32/i43/122240.htm
DOI: https://dx.doi.org/10.3748/wjg.122240

Pattarawongpaiboon C, Thaimai P, Boonkaya S, Sriyudthsak K, Lertsanguansinchai S, Ananchuensook P, Sriphoosanaphan S, Pinjaroen N, Treeprasertsuk S, Komolmit P, Thanapirom K. Changes in liver and spleen stiffness after transarterial chemoembolization for hepatocellular carcinoma and role in predicting hepatic decompensation. World J Gastroenterol 2026; 32(43): 122240 [DOI: 10.3748/wjg.122240]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.